Cassava Sciences (NASDAQ:SAVA) held a conference this morning announcing promising Phase 2b trial results in treating patients with mild-moderate Alzheimer’s Disease. The company uses the drug Sumifilam to treat AD by reducing neurodegeneration and neuroinflammation. The results announced via conference call concluded that the data shows a promising increase in cognitive bio-markers within AD patients – an impressive feat for the AD treatment pioneer. The results disclosed this morning are quite strong however we will breakdown the results of the dataset and what the imminent future looks like for shareholders.
Table of Contents 1. Introduction 2. Results summary 3. What the future looks like for Cassava investors?
- The phase 2b trial results showed promising data in treating mild to moderate AD patients
- The results show consistency with the Phase 2a trials, a positive sign the drug holds benefit to AD patients
- “No other clinical-stage drug candidate has improved an entire panel of biomarkers of disease pathology, neurodegeneration and neuroinflammation, and appears to benefit cognition
- The next steps outline the development of the Phase 3 efficacy program, after the End of Phase 2 meeting with the FDA
- “98% of patients treated with Sumifilam 50 mg for 28 days showed improvements in validated biomarkers of AD pathology, neuroinflammation and neurodegeneration with no safety issues.”
- Cognitive markers were up, however only directional improvement was seen in the improvement of spatial working memory – 17%-46%
- See all data here.
What the future looks like for Cassava investors?
Before I begin, I am obliged to remind our viewers that this is not advice but rather investment commentary from extensive research
The dataset provided this morning shows positive signs for long term shareholders of Cassava, however the Phase 3 program will be the company’s biggest challenge to date. The data is consistent from Phase 2a to Phase 2b, which does suggest Sumifilam has the potential to improve the cognitive bio-markers in AD patients on a larger scale. Investors have pounced on the positive Phase 2b trials this morning, marking an incredible surge of 148% premarket.
SAVA will likely drawback after open, before finding equilibrium as speculators withdraw with profits. Longer term investors will be less phased by the added volatility, as the key focus is delivering strong Phase 3 trials in 2021. One of the key concerns for current stakeholders is if SAVA can produce stronger correlative data with spatial working memory in AD patients. Cassava advised the directional relationship is limited due to the size of the trial, so Phase 3 should shed some light on the ability of the AD drug in patients.
Want access to free, uncomplicated, and smart COVID-19 Strategies then click below?
If you enjoy our article or are wanting to learn more, you can subscribe to us by turning on notifications to get updates when we post a new article. From all of us at YIG, thank you for the support.
The information above is not financial advice. Youth Investment Group has no liability for personal financial interests or investment decisions. You should make your own investment decisions based upon your own research and what you believe is best for you.